Cargando…
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise patients experiencing hyperprogression (HPD) a...
Autores principales: | Zulato, Elisabetta, Del Bianco, Paola, Nardo, Giorgia, Attili, Ilaria, Pavan, Alberto, Boscolo Bragadin, Andrea, Marra, Ludovica, Pasello, Giulia, Fassan, Matteo, Calabrese, Fiorella, Guarneri, Valentina, Conte, Pier Franco, Indraccolo, Stefano, Bonanno, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681746/ https://www.ncbi.nlm.nih.gov/pubmed/36175621 http://dx.doi.org/10.1038/s41416-022-01978-1 |
Ejemplares similares
-
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020) -
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
por: Pavan, Alberto, et al.
Publicado: (2021) -
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021) -
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
por: Bonanno, Laura, et al.
Publicado: (2019) -
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)